Harnessing the Exposome to Diagnose Autism - Manish Arora, Linusbio @Synchrony2022
Вставка
- Опубліковано 5 вер 2024
- Manish Arora BDS, MPH, PHD is the CEO of Linus Biotechnology, a patient-centric, precision exposome medicine company. Originating from the world’s leading exposome laboratory at Mount Sinai Health System, Linus has developed a technology platform that builds on breakthroughs in exposome sequencing that provide a molecular map over time to study the non-genomic components of health and disease.
LinusBio’s program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including Autism Spectrum Disorder.
LinusBio received US FDA Breakthrough Designation and European Union CE Mark for its autism biomarker that can be applied as early as birth. The LinusBio platform is also being used in Phase 2 autism drug trials, and separately in a Phase 2 trial of a microbiome product with Novozymes.
🎥 This talk was part of was part of Synchrony 2022 Online Symposium - 'From Bench to Biopharma', organised by the The BRAIN Foundation
🎥 For more Synchrony 2022 talks and highlights: • Synchrony Symposium 20...
🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠
Synchrony synchronysympo... is the first and only international symposium on translational research in #autism, that brings together academia, #biotech, pharmaceutical companies and #venture partners from around the world with the mission to improve health and quality of life of people with #autismspectrumdisorder.
🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠
The BRAIN Foundation brainfoundatio... is a 501c(3) non-profit. The founders of BRAIN envision a world where every child and adult on the autism spectrum is healthy, participates fully in education and employment, and has a better quality of life. It aims to catalyze research that results in evidence-based interventions for the disabilities associated with autism, and also results in better medical standard of care.
To accomplish this, it funds impactful research through #philanthropy and our network of partners in the venture, corporate, and grassroots community.